Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-1192P is a pseudogene that originates from the U6 small nuclear RNA gene family[1][4]. While U6 snRNA plays a critical role as a component of the spliceosomal machinery responsible for precursor mRNA splicing in eukaryotes[3][5], pseudogenes like RNU6-1192P are genomic DNA sequences similar to their functional gene counterparts but are typically non-functional due to mutations or lack of regulatory elements[1][6][4][7]. U6 snRNA and its pseudogenes are widely distributed in vertebrate genomes[5][6] and can serve as evolutionary markers for retrotransposition activity[6]. However, RNU6-1192P itself does not produce any functional RNA or protein product and has not been implicated in disease, therapeutic intervention, or diagnostic use[1][4][6]. Pseudogenes of U6 snRNA may contribute to genome evolution or serve as templates in retrotransposition, but individually, copies such as RNU6-1192P have no established direct role in cellular or pathological processes[6][7].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1192, pseudogene (RNU6-1192P).